OnCo
technologiesTechnologyStandard of care

HPV DNA testing and self-sampling

A swab tested for the virus that causes cervical cancer, more accurate than the Pap smear and doable at home.

HPV primary screening detects CIN3+ more sensitively than cytology and allows 5-year intervals; it is the WHO-recommended screening test and is standard in the Netherlands, Australia, England, and increasingly the US. Self-collected vaginal samples perform as well as clinician samples for PCR-based tests; the FDA approved self-collection in health-care settings in May 2024 and the first at-home kit in 2025. Extended genotyping and methylation triage (FAM19A4/miR124-2) reduce colposcopy referrals. Point-of-care and AI-read tests target low-resource settings.

Generic schematic · not to scale · placeholder for the early detection front
Plasma · Early signal

How it works

Nucleic acid amplification or hybrid capture of high-risk HPV types (16, 18 and 12 others) from cervical or vaginal cells.

Strengths
  • Higher sensitivity for precancer than cytology
  • Self-sampling reaches never-screened women
  • Long safe intervals cut cost
Limitations
  • Lower specificity in young women (transient infection)
  • Needs triage (cytology, genotyping, methylation) before colposcopy
Since
2003

Key papers

3top

Latest papers

top
Literature trend1 papers in the last 12 monthsHow this is computed
Latest papers · live from Europe PMC
Open in Europe PMC

Query for this technology: (TITLE:"HPV DNA testing and self-sampling" OR ABSTRACT:"HPV DNA testing and self-sampling") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about HPV DNA testing and self-sampling, not a curated reading list.

Connected

22top

Pages like this

not linked directly; found by shared links